A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review

A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review

Lorlatinib is a third-generation ALK inhibitor that can overcome the largest number of acquired ALK resistance mutations, including the solvent-front mutation G1202R. Here, we report, for the first time, a novel, sequentially-evolved EML4-ALK variant 3 G1202R/S1206Y double mutation in cis detected i...

Full description

Bibliographic Details
Main Authors: Viola W. Zhu, MD, PhD, Misako Nagasaka, MD, Russell Madison, BA, Alexa B. Schrock, PhD, Jean Cui, PhD, Sai-Hong Ignatius Ou, MD, PhD
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:JTO Clinical and Research Reports
Subjects:
G1202R
S1206Y
Double mutation
Lorlatinib resistance
ALK+ NSCLC
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320301624

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320301624

Similar Items